Vancouver, Canada, Sept. 06, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (“PCT”) for its innovative combination of 3,4-Methylenedioxymethamphetamine (MDMA) with N-Acylethanolamines.
https://f4634ab37f18abc97bd75bcc15059f42.safeframe.googlesyndication.com/safeframe/1-0-40/html/container.html
The patent application was filed as part of the Company’s ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) (“SciSparc”), a specialty pharmaceutical company in the clinical trial phase, dedicated to developing treatments for central nervous system disorders.
Under this collaboration, the two companies are researching innovative combination therapies that integrate psychedelic molecules with the N-Acylethanolamines family, including Palmitoylethanolamide (PEA). To date, thirteen patents related to this collaboration have been filed with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, commented on the announcement: “The continued evolution of our patent portfolio reflects our strategic commitment to bringing innovative and effective treatments to market. While MDMA has shown promising clinical benefits as a standalone therapy, it also presents potential dose-limiting toxicities. Our unique combination of MDMA and PEA is designed to address critical safety concerns raised by the FDA regarding MDMA’s safety profile. By combining MDMA with PEA, we aim to significantly reduce the MDMA dosage, thereby minimizing potential risks while maintaining therapeutic efficacy. We believe our strategy of combining psychedelic molecules and N-Acylethanolamines, could pave the way for a new era in the treatment of mental health disorders and addictions.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
https://f4634ab37f18abc97bd75bcc15059f42.safeframe.googlesyndication.com/safeframe/1-0-40/html/container.html
The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
SciSparc Ltd. (SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.